Repligen Corporation (NASDAQ:RGEN) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday.
Several other analysts have also weighed in on the company. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Thursday, May 11th. First Analysis reaffirmed an “equal weight” rating and set a $40.00 target price on shares of Repligen Corporation in a report on Friday, April 21st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $37.25.
Shares of Repligen Corporation (NASDAQ:RGEN) opened at 38.53 on Wednesday. The firm’s 50-day moving average price is $38.49 and its 200-day moving average price is $33.87. Repligen Corporation has a 52-week low of $21.11 and a 52-week high of $40.48. The firm has a market capitalization of $1.31 billion, a PE ratio of 101.66 and a beta of 1.30.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.02. The firm had revenue of $30.59 million during the quarter, compared to analyst estimates of $29.28 million. Repligen Corporation had a return on equity of 9.57% and a net margin of 11.93%. Repligen Corporation’s quarterly revenue was up 21.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.12 earnings per share. On average, equities analysts predict that Repligen Corporation will post $0.56 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Repligen Corporation (RGEN) Rating Lowered to Buy at BidaskClub” was originally published by sleekmoney and is the sole property of of sleekmoney. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://sleekmoney.com/repligen-corporation-rgen-rating-lowered-to-buy-at-bidaskclub/1913742.html.
In other news, Director Thomas F. Ryan, Jr. sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $34.83, for a total transaction of $139,320.00. Following the completion of the transaction, the director now directly owns 12,594 shares of the company’s stock, valued at $438,649.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen A. Dawes sold 2,521 shares of the company’s stock in a transaction that occurred on Tuesday, March 21st. The shares were sold at an average price of $34.12, for a total value of $86,016.52. Following the transaction, the director now directly owns 95,764 shares of the company’s stock, valued at $3,267,467.68. The disclosure for this sale can be found here. Insiders have sold 18,737 shares of company stock valued at $648,254 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Repligen Corporation by 143,196.5% in the first quarter. BlackRock Inc. now owns 4,664,302 shares of the biotechnology company’s stock valued at $164,187,000 after buying an additional 4,661,047 shares during the period. TimesSquare Capital Management LLC raised its position in Repligen Corporation by 35.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,970,725 shares of the biotechnology company’s stock valued at $69,370,000 after buying an additional 512,300 shares during the period. Norges Bank bought a new position in Repligen Corporation during the fourth quarter valued at approximately $8,527,000. Macquarie Group Ltd. raised its position in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock valued at $9,852,000 after buying an additional 264,659 shares during the period. Finally, MARSHALL WACE ASIA Ltd bought a new position in Repligen Corporation during the first quarter valued at approximately $9,006,000. 97.06% of the stock is owned by institutional investors.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/repligen-corporation-rgen-rating-lowered-to-buy-at-bidaskclub/1913742.html
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.